FDA panel votes against Aveo’s kidney cancer drug

Your Health Matters

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver SpringBy Toni Clarke (Reuters) – An advisory panel to the Food and Drug Administration recommended that the agency reject a kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc, saying data from the clinical trial were inconsistent. In a 13-1 vote on Thursday, the panel said Aveo had not shown that the drug's benefits outweighed its risks in a well-controlled study, and said a second trial would be needed before the drug, tivozanib, should be approved. Aveo's shares fell as much as 57 percent on Thursday. …

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave